Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating infections

Platelets

Volumn 10, Issue 1, 1999, Pages 17-23

  Foss, B ^a   Nesthus, I ^a   Bergheim, J ^a   Bruserud, Øystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; GROWTH FACTOR; STEM CELL FACTOR; THROMBOPOIETIN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; FEMALE; HUMAN; HUMAN CELL; INFECTION COMPLICATION; MALE; MEGAKARYOCYTE; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS;

BACTERIA (MICROORGANISMS);

EID: 0033005647     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109976301     Document Type: Article

References (31)

1. Meyer RJ, Davies RB, Schiffer CA et al. Intensive postremission therapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
2. Hoeltzer, D. Treatment of acute lymphoblastic leukaemia. Semin Oncol 1994; 31: 1-15.
3. Bruserud Ø, Peen E, Halstensen A, Solberg CO. Serum levels of soluble adhesion molecules and cytokines in patients with acute leukaemia. Leuk Lymphoma 1996; 23: 423-30.
4. Steinshamn S, Brekke O-L, Waage A. Soluble tumor necrosis factor receptors, tumor necrosis factor and Interleukin 6 in serum in granulocytopenic patients with fever. Br J Haematol 1995; 89: 719-24.
5. Ostermann H, Rothenburger M, Mesters RM, van de Loo J, Kienast J. Cytokine response to infection in patients with acute myelogenous leukemia following intensive chemotherapy. Br J Haematol 1994; 88: 332-7.
6. Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J. Endotoxin, Interleukin 6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995; 27: 39-43.
7. Bruserud Ø, Ulvestad E, Halstensen A, Berentsen S, Bergheim J, Nesthus I. Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia. Eur J Haematol 1997; 59: 269-75.
8. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86: 419-31.
9. Drexler HG, Quentmeier H. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Leukemia 1996; 10: 1405-21.
10. Burstein SA. Cytokines, platelet production and hemostasis. Platelets 1997; 8: 93-104.
11. Debili N, Wendling F, Cosman D et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85: 391-401.
12. Avraham H, Vannier E, Cowley S et al. Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood 1992; 79: 365-71.
13. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994; 54: 3049-53.
14. Grabarek J, Groopman JE, Lyles YR et al. Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 1994; 269: 21718-24.
15. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-8.
16. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567-73.
17. Fielder PJ, Gurney AL, Stefanich E et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-61.
18. Harker LA, Hunt P, Marzec UM et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-44.
19. Harker LA, Marzec UM, Hunt P et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-21.
20. Tanimukai S, Kimura T, Sakabe H et al. Recombinant human, c-Mpl ligand (thrombopoietin) not only acts on megakaryocyte progenitors, but also on erythroid and multipotential progenitors in vitro. Exp Hematol 1997; 25: 1025-33.
21. Neelis KJ, Dubbelman YD, Quingliang L, Thomas GR, Eaton DL, Wagemaker G. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol 1997; 25: 1084-93.
22. + cells in a serum-free system. Br J Haematol 1996; 93: 13-17.
23. Briddel RA, Bruno E, Cooper RJ, Brandt JE, Hoffman R. Effects of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 1991; 78: 2854-9.
24. Andrews RG, Knitter GH, Bartelmez SH et al. Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood 1991; 78: 1975-80.
25. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054-62.
26. Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemostas 1995; 74: 1541-5.
27. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762-8.
28. Oda A, Miyakawa Y, Druker BJ et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664-70.
29. Rodriguez-Linares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J 1996; 316: 93-8.
30. Oda A, Ozaki K, Druker BJ et al. p120 c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. Blood 1996; 88: 1330-8.
31. Shinjo K, Takeshita A, Nakamura S, et al. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia. Leukemia 1998; 12: 295-300.